Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Virology Journal
Published in: Virology Journal 1/2012

Open Access 01-12-2012 | Research

Induction of ebolavirus cross-species immunity using retrovirus-like particles bearing the Ebola virus glycoprotein lacking the mucin-like domain

Authors: Wu Ou, Josie Delisle, Jerome Jacques, Joanna Shih, Graeme Price, Jens H Kuhn, Vivian Wang, Daniela Verthelyi, Gerardo Kaplan, Carolyn A Wilson

Published in: Virology Journal | Issue 1/2012

Login to get access

Abstract

Background

The genus Ebolavirus includes five distinct viruses. Four of these viruses cause hemorrhagic fever in humans. Currently there are no licensed vaccines for any of them; however, several vaccines are under development. Ebola virus envelope glycoprotein (GP1,2) is highly immunogenic, but antibodies frequently arise against its least conserved mucin-like domain (MLD). We hypothesized that immunization with MLD-deleted GP1,2 (GPΔMLD) would induce cross-species immunity by making more conserved regions accessible to the immune system.

Methods

To test this hypothesis, mice were immunized with retrovirus-like particles (retroVLPs) bearing Ebola virus GPΔMLD, DNA plasmids (plasmo-retroVLP) that can produce such retroVLPs in vivo, or plasmo-retroVLP followed by retroVLPs.

Results

Cross-species neutralizing antibody and GP1,2-specific cellular immune responses were successfully induced.

Conclusion

Our findings suggest that GPΔMLD presented through retroVLPs may provide a strategy for development of a vaccine against multiple ebolaviruses. Similar vaccination strategies may be adopted for other viruses whose envelope proteins contain highly variable regions that may mask more conserved domains from the immune system.
Appendix
Available only for authorised users
Literature
1.
Kuhn JH, Becker S, Ebihara H, Geisbert TW, Johnson KM, Kawaoka Y, Lipkin WI, Negredo AI, Netesov SV, Nichol ST, et al.: Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations. Arch Virol 2010, 155: 2083-2103. 10.1007/s00705-010-0814-xPubMedPubMedCentralCrossRef
2.
Ascenzi P, Bocedi A, Heptonstall J, Capobianchi MR, Di Caro A, Mastrangelo E, Bolognesi M, Ippolito G: Ebolavirus and Marburgvirus: insight the Filoviridae family. Mol Aspects Med 2008, 29: 151-185. 10.1016/j.mam.2007.09.005PubMedCrossRef
3.
Feldmann H, Jones S, Klenk HD, Schnittler HJ: Ebola virus: from discovery to vaccine. Nat Rev Immunol 2003, 3: 677-685. 10.1038/nri1154PubMedCrossRef
4.
5.
Richardson JS, Dekker JD, Croyle MA, Kobinger GP: Recent advances in Ebolavirus vaccine development. Hum Vaccin 2010, 6: 439-449. 10.4161/hv.6.6.11097PubMedCrossRef
6.
Falzarano D, Geisbert TW, Feldmann H: Progress in filovirus vaccine development: evaluating the potential for clinical use. Expert Rev Vaccines 2011, 10: 63-77. 10.1586/erv.10.152PubMedPubMedCentralCrossRef
7.
Jeffers SA, Sanders DA, Sanchez A: Covalent modifications of the ebola virus glycoprotein. J Virol 2002, 76: 12463-12472. 10.1128/JVI.76.24.12463-12472.2002PubMedPubMedCentralCrossRef
8.
Lee JE, Fusco ML, Hessell AJ, Oswald WB, Burton DR, Saphire EO: Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nat 2008, 454: 177-182. 10.1038/nature07082CrossRef
9.
Francica JR, Varela-Rohena A, Medvec A, Plesa G, Riley JL, Bates P: Steric shielding of surface epitopes and impaired immune recognition induced by the ebola virus glycoprotein. PLoS Pathog 2010, 6: e1001098. 10.1371/journal.ppat.1001098PubMedPubMedCentralCrossRef
10.
Reynard O, Borowiak M, Volchkova VA, Delpeut S, Mateo M, Volchkov VE: Ebolavirus glycoprotein GP masks both its own epitopes and the presence of cellular surface proteins. J Virol 2009, 83: 9596-9601. 10.1128/JVI.00784-09PubMedPubMedCentralCrossRef
11.
Dowling W, Thompson E, Badger C, Mellquist JL, Garrison AR, Smith JM, Paragas J, Hogan RJ, Schmaljohn C: Influences of glycosylation on antigenicity, immunogenicity, and protective efficacy of ebola virus GP DNA vaccines. J Virol 2007, 81: 1821-1837. 10.1128/JVI.02098-06PubMedPubMedCentralCrossRef
12.
Shahhosseini S, Das D, Qiu X, Feldmann H, Jones SM, Suresh MR: Production and characterization of monoclonal antibodies against different epitopes of Ebola virus antigens. J Virol Methods 2007, 143: 29-37. 10.1016/j.jviromet.2007.02.004PubMedCrossRef
13.
Takada A, Ebihara H, Feldmann H, Geisbert TW, Kawaoka Y: Epitopes required for antibody-dependent enhancement of Ebola virus infection. J Infect Dis 2007,196(Suppl 2):S347-356.PubMedCrossRef
14.
Wilson JA, Hevey M, Bakken R, Guest S, Bray M, Schmaljohn AL, Hart MK: Epitopes involved in antibody-mediated protection from Ebola virus. Sci 2000, 287: 1664-1666. 10.1126/science.287.5458.1664CrossRef
15.
Manicassamy B, Wang J, Jiang H, Rong L: Comprehensive analysis of ebola virus GP1 in viral entry. J Virol 2005, 79: 4793-4805. 10.1128/JVI.79.8.4793-4805.2005PubMedPubMedCentralCrossRef
16.
Simmons G, Wool-Lewis RJ, Baribaud F, Netter RC, Bates P: Ebola virus glycoproteins induce global surface protein down-modulation and loss of cell adherence. J Virol 2002, 76: 2518-2528. 10.1128/jvi.76.5.2518-2528.2002PubMedPubMedCentralCrossRef
17.
Yang Z, Delgado R, Xu L, Todd RF, Nabel EG, Sanchez A, Nabel GJ: Distinct cellular interactions of secreted and transmembrane Ebola virus glycoproteins. Sci 1998, 279: 1034-1037. 10.1126/science.279.5353.1034CrossRef
18.
Dube D, Brecher MB, Delos SE, Rose SC, Park EW, Schornberg KL, Kuhn JH, White JM: The primed ebolavirus glycoprotein (19-kilodalton GP1,2): sequence and residues critical for host cell binding. J Virol 2009, 83: 2883-2891. 10.1128/JVI.01956-08PubMedPubMedCentralCrossRef
19.
Kuhn JH, Radoshitzky SR, Guth AC, Warfield KL, Li W, Vincent MJ, Towner JS, Nichol ST, Bavari S, Choe H, et al.: Conserved receptor-binding domains of Lake Victoria marburgvirus and Zaire ebolavirus bind a common receptor. J Biol Chem 2006, 281: 15951-15958. 10.1074/jbc.M601796200PubMedCrossRef
20.
Buonaguro L, Tornesello ML, Buonaguro FM: Virus-like particles as particulate vaccines. Curr HIV Res 2010, 8: 299-309. 10.2174/157016210791208659PubMedCrossRef
21.
Chackerian B: Virus-like particles: flexible platforms for vaccine development. Expert Rev Vaccines 2007, 6: 381-390. 10.1586/14760584.6.3.381PubMedCrossRef
22.
Jennings GT, Bachmann MF: The coming of age of virus-like particle vaccines. Biol Chem 2008, 389: 521-536. 10.1515/BC.2008.064PubMedCrossRef
23.
Apostolopoulos V, Weiner DB: Development of more efficient and effective DNA vaccines. Expert Rev Vaccines 2009, 8: 1133-1134. 10.1586/erv.09.94PubMedCrossRef
24.
Dupuy LC, Schmaljohn CS: DNA vaccines for biodefense. Expert Rev Vaccines 2009, 8: 1739-1754. 10.1586/erv.09.132PubMedCrossRef
25.
Liu MA: DNA vaccines: an historical perspective and view to the future. Immunol Rev 2011, 239: 62-84. 10.1111/j.1600-065X.2010.00980.xPubMedCrossRef
26.
Bellier B, Dalba C, Clerc B, Desjardins D, Drury R, Cosset FL, Collins M, Klatzmann D: DNA vaccines encoding retrovirus-based virus-like particles induce efficient immune responses without adjuvant. Vaccine 2006, 24: 2643-2655. 10.1016/j.vaccine.2005.11.034PubMedCrossRef
27.
Bellier B, Huret C, Miyalou M, Desjardins D, Frenkiel MP, Despres P, Tangy F, Dalba C, Klatzmann D: DNA vaccines expressing retrovirus-like particles are efficient immunogens to induce neutralizing antibodies. Vaccine 2009, 27: 5772-5780. 10.1016/j.vaccine.2009.07.059PubMedCrossRef
28.
Desjardins D, Huret C, Dalba C, Kreppel F, Kochanek S, Cosset FL, Tangy F, Klatzmann D, Bellier B: Recombinant retrovirus-like particle forming DNA vaccines in prime-boost immunization and their use for hepatitis C virus vaccine development. J Gene Med 2009, 11: 313-325. 10.1002/jgm.1307PubMedCrossRef
29.
Chang DC, Liu WJ, Anraku I, Clark DC, Pollitt CC, Suhrbier A, Hall RA, Khromykh AA: Single-round infectious particles enhance immunogenicity of a DNA vaccine against West Nile virus. Nat Biotechnol 2008, 26: 571-577. 10.1038/nbt1400PubMedCrossRef
30.
Chege GK, Shephard EG, Meyers A, van Harmelen J, Williamson C, Lynch A, Gray CM, Rybicki EP, Williamson AL: HIV-1 subtype C Pr55gag virus-like particle vaccine efficiently boosts baboons primed with a matched DNA vaccine. J Gen Virol 2008, 89: 2214-2227. 10.1099/vir.0.83501-0PubMedCrossRef
31.
Dalba C, Bellier B, Kasahara N, Klatzmann D: Replication-competent vectors and empty virus-like particles: new retroviral vector designs for cancer gene therapy or vaccines. Mol Ther 2007, 15: 457-466. 10.1038/sj.mt.6300054PubMedCrossRef
32.
Martin JE, Sullivan NJ, Enama ME, Gordon IJ, Roederer M, Koup RA, Bailer RT, Chakrabarti BK, Bailey MA, Gomez PL, et al.: A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol 2006, 13: 1267-1277. 10.1128/CVI.00162-06PubMedPubMedCentralCrossRef
33.
Mellquist-Riemenschneider JL, Garrison AR, Geisbert JB, Saikh KU, Heidebrink KD, Jahrling PB, Ulrich RG, Schmaljohn CS: Comparison of the protective efficacy of DNA and baculovirus-derived protein vaccines for EBOLA virus in guinea pigs. Virus Res 2003, 92: 187-193. 10.1016/S0168-1702(02)00338-6PubMedCrossRef
34.
Sullivan NJ, Geisbert TW, Geisbert JB, Xu L, Yang ZY, Roederer M, Koup RA, Jahrling PB, Nabel GJ: Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nat 2003, 424: 681-684. 10.1038/nature01876CrossRef
35.
Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ: Development of a preventive vaccine for Ebola virus infection in primates. Nat 2000, 408: 605-609. 10.1038/35046108CrossRef
36.
Sun Y, Carrion R Jr, Ye L, Wen Z, Ro YT, Brasky K, Ticer AE, Schwegler EE, Patterson JL, Compans RW, Yang C: Protection against lethal challenge by Ebola virus-like particles produced in insect cells. Virol 2009, 383: 12-21. 10.1016/j.virol.2008.09.020CrossRef
37.
Warfield KL, Bosio CM, Welcher BC, Deal EM, Mohamadzadeh M, Schmaljohn A, Aman MJ, Bavari S: Ebola virus-like particles protect from lethal Ebola virus infection. Proc Natl Acad Sci USA 2003, 100: 15889-15894. 10.1073/pnas.2237038100PubMedPubMedCentralCrossRef
38.
Warfield KL, Posten NA, Swenson DL, Olinger GG, Esposito D, Gillette WK, Hopkins RF, Costantino J, Panchal RG, Hartley JL, et al.: Filovirus-like particles produced in insect cells: immunogenicity and protection in rodents. J Infect Dis 2007,196(Suppl 2):S421-429.PubMedCrossRef
39.
Kaletsky RL, Simmons G, Bates P: Proteolysis of the Ebola virus glycoproteins enhances virus binding and infectivity. J Virol 2007, 81: 13378-13384. 10.1128/JVI.01170-07PubMedPubMedCentralCrossRef
40.
Mpanju OM, Towner JS, Dover JE, Nichol ST, Wilson CA: Identification of two amino acid residues on Ebola virus glycoprotein 1 critical for cell entry. Virus Res 2006, 121: 205-214. 10.1016/j.virusres.2006.06.002PubMedCrossRef
41.
Wool-Lewis RJ, Bates P: Characterization of Ebola virus entry by using pseudotyped viruses: identification of receptor-deficient cell lines. J Virol 1998, 72: 3155-3160.PubMedPubMedCentral
42.
Ou W, Delisle J, Konduru K, Bradfute S, Radoshitzky SR, Retterer C, Kota K, Bavari S, Kuhn JH, Jahrling PB, et al.: Development and characterization of rabbit and mouse antibodies against ebolavirus envelope glycoproteins. J Virol Methods 2011, 174: 99-109. 10.1016/j.jviromet.2011.04.003PubMedPubMedCentralCrossRef
43.
Konduru K, Bradfute SB, Jacques J, Manangeeswaran M, Nakamura S, Morshed S, Wood SC, Bavari S, Kaplan GG: Ebola virus glycoprotein Fc fusion protein confers protection against lethal challenge in vaccinated mice. Vaccine 2011, 29: 2968-2977. 10.1016/j.vaccine.2011.01.113PubMedPubMedCentralCrossRef
44.
Sullivan NJ, Geisbert TW, Geisbert JB, Shedlock DJ, Xu L, Lamoreaux L, Custers JH, Popernack PM, Yang ZY, Pau MG, et al.: Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med 2006, 3: e177. 10.1371/journal.pmed.0030177PubMedPubMedCentralCrossRef
45.
Martinez O, Valmas C, Basler CF: Ebola virus-like particle-induced activation of NF-kappaB and Erk signaling in human dendritic cells requires the glycoprotein mucin domain. Virol 2007, 364: 342-354. 10.1016/j.virol.2007.03.020CrossRef
46.
Saifuddin M, Hedayati T, Atkinson JP, Holguin MH, Parker CJ, Spear GT: Human immunodeficiency virus type 1 incorporates both glycosyl phosphatidylinositol-anchored CD55 and CD59 and integral membrane CD46 at levels that protect from complement-mediated destruction. J Gen Virol 1997,78(Pt 8):1907-1911.PubMedCrossRef
47.
Saifuddin M, Parker CJ, Peeples ME, Gorny MK, Zolla-Pazner S, Ghassemi M, Rooney IA, Atkinson JP, Spear GT: Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1. J Exp Med 1995, 182: 501-509. 10.1084/jem.182.2.501PubMedCrossRef
48.
Spear GT, Lurain NS, Parker CJ, Ghassemi M, Payne GH, Saifuddin M: Host cell-derived complement control proteins CD55 and CD59 are incorporated into the virions of two unrelated enveloped viruses. Human T cell leukemia/lymphoma virus type I (HTLV-I) and human cytomegalovirus (HCMV). J Immunol 1995, 155: 4376-4381.PubMed
49.
Takefman DM, Spear GT, Saifuddin M, Wilson CA: Human CD59 incorporation into porcine endogenous retrovirus particles: implications for the use of transgenic pigs for xenotransplantation. J Virol 2002, 76: 1999-2002. 10.1128/JVI.76.4.1999-2002.2002PubMedPubMedCentralCrossRef
50.
Finer MH, Dull TJ, Qin L, Farson D, Roberts MR: kat: a high-efficiency retroviral transduction system for primary human T lymphocytes. Blood 1994, 83: 43-50.PubMed
51.
Olinger GG, Bailey MA, Dye JM, Bakken R, Kuehne A, Kondig J, Wilson J, Hogan RJ, Hart MK: Protective cytotoxic T-cell responses induced by venezuelan equine encephalitis virus replicons expressing Ebola virus proteins. J Virol 2005, 79: 14189-14196. 10.1128/JVI.79.22.14189-14196.2005PubMedPubMedCentralCrossRef
52.
Rao M, Bray M, Alving CR, Jahrling P, Matyas GR: Induction of immune responses in mice and monkeys to Ebola virus after immunization with liposome-encapsulated irradiated Ebola virus: protection in mice requires CD4(+) T cells. J Virol 2002, 76: 9176-9185. 10.1128/JVI.76.18.9176-9185.2002PubMedPubMedCentralCrossRef
53.
Ou W, King H, Delisle J, Shi D, Wilson CA: Phenylalanines at positions 88 and 159 of Ebolavirus envelope glycoprotein differentially impact envelope function. Virol 2010, 396: 135-142. 10.1016/j.virol.2009.10.028CrossRef
54.
Wilson CA, Eiden MV: Viral and cellular factors governing hamster cell infection by murine and gibbon ape leukemia viruses. J Virol 1991, 65: 5975-5982.PubMedPubMedCentral
55.
Tompkins SM, Zhao ZS, Lo CY, Misplon JA, Liu T, Ye Z, Hogan RJ, Wu Z, Benton KA, Tumpey TM, Epstein SL: Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg Infect Dis 2007, 13: 426-435. 10.3201/eid1303.061125PubMedPubMedCentralCrossRef
Metadata
Title
Induction of ebolavirus cross-species immunity using retrovirus-like particles bearing the Ebola virus glycoprotein lacking the mucin-like domain
Authors
Wu Ou
Josie Delisle
Jerome Jacques
Joanna Shih
Graeme Price
Jens H Kuhn
Vivian Wang
Daniela Verthelyi
Gerardo Kaplan
Carolyn A Wilson
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2012
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/1743-422X-9-32

Other articles of this Issue 1/2012

Virology Journal 1/2012 Go to the issue

Methodology

An improved respiratory syncytial virus neutralization assay based on the detection of green fluorescent protein expression and automated plaque counting

Research

Evaluating viral interference between Influenza virus and Newcastle disease virus using real-time reverse transcription–polymerase chain reaction in chicken eggs

Research

Surveillance in eastern India (2007-2009) revealed reassortment event involving ns and PB1-F2 gene segments among co-circulating influenza a subtypes

Research

Induction of cross-protection against influenza A virus by DNA prime-intranasal protein boost strategy based on nucleoprotein

Research

First time molecular detection and phylogenetic relationships of torque teno sus virus 1 and 2 in domestic pigs in Uganda: further evidence for a global distribution

Research

New insights regarding HCV-NS5A structure/function and indication of genotypic differences
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits